Beth Seidenberg, MD joined Kleiner Perkins Caufield & Byers in May 2005, to work in the life sciences area. She is currently on the Board of Directors of BioCryst Pharmaceuticals, HX Diagnostics, Anza Therapeutics, Breathe Technologies, Arresto Biosciences, and 2 stealth companies. Her primary focus is in novel therapeutics to treat unmet medical needs.
Dr. Seidenberg was formerly the Senior Vice President, Global Development, and Chief Medical Officer at Amgen. Prior to joining Amgen, she was a senior executive in research and development at Bristol-Myers Squibb and Merck & Co. She began her career in basic and clinical research at the National Institutes of Health specializing in immunology and infectious diseases. In total, she introduced 10 innovative products to market and achieved over 40 regulatory approvals (including new indications and formulations) on a worldwide basis.
Dr. Seidenberg received her B.S. from Barnard College and her medical degree from the University Of Miami School Of Medicine. Her post-graduate training was completed at Johns Hopkins and the National Institutes of Health.